-
平臺編號：bio-131659
-
細胞信息： WM35
-
規(guī)格：1×10?cells/T25培養(yǎng)瓶
-
服務費用：
加載中…… - 訂購
-
注意事項：僅用于科學研究或者工業(yè)應用等非醫(yī)療目的不可用于人類或動物的臨床診斷或治療，非藥用，非食用（產(chǎn)品信息以出庫為準）
人黑色素瘤細胞WM35
細胞名稱：人黑色素瘤細胞WM35
產(chǎn)品規(guī)格：T25培養(yǎng)瓶x1；1.5ml凍存管x2
細胞數(shù)量：1x10^6；1x10^6
保存溫度：37℃；-198℃
運輸方式：常溫保溫運輸；干冰運輸
安全等級：1
用途限制：僅供科研2類
培養(yǎng)體系：DMEM高糖培養(yǎng)基+10%FBS+1%三抗
培養(yǎng)溫度：37℃
二氧化碳濃度：5%
簡介：人黑色素瘤細胞WM35取自24歲女性供體
注釋
Part of:Cancer Cell Line Encyclopedia(CCLE)project.
Part of:COSMIC cell lines project.
Part of:Wistar Institute melanoma cell line collection.
Microsatellite instability:Stable(MSS)(Sanger).
Omics:Deep exome analysis.
Omics:DNA methylation analysis.
Omics:Transcriptome analysis.
Caution:The reported STR profile from Wistar of this cell line was changed at one point between February 2016 when we retrieved them and entered them in the Cellosaurus and May 2018.The major changes were:D18S51:20->14,15 and FGA:19->19,24.
基因突變
Heterozygous for BRAF p.Val600Glu(c.1799T>A)(PubMed=18632627;Wistar).
HLA信息
/
STR信息
Amelogenin X
CSF1PO 10
D2S1338 18,25
D3S1358 16,18
D5S818 11,12
D7S820 10,13
D8S1179 11,13
D13S317 11
D16S539 12,13
D18S51 14,15
D19S433 15,16
D21S11 29,32.2
FGA 19,24
TH01 9.3
TPOX 8
vWA 17
參考文獻
PubMed=23039341;DOI=10.1186/1476-4598-11-75
Byron S.A.,Loch D.C.,Wellens C.L.,Wortmann A.,Wu J.,Wang J.,Nomoto K.,Pollock P.M.
Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status.
Mol.Cancer 11:75-75(2012)
PubMed=27087056;DOI=10.1038ep24569
Haridas P.,McGovern J.A.,Kashyap A.S.,McElwain D.L.S.,Simpson M.J.
Standard melanoma-associated markers do not identify the MM127 metastatic melanoma cell line.
Sci.Rep.6:24569-24569(2016)
PubMed=27397505;DOI=10.1016/j.cell.2016.06.017
Iorio F.,Knijnenburg T.A.,Vis D.J.,Bignell G.R.,Menden M.P.,Schubert M.,Aben N.,Goncalves E.,Barthorpe S.,Lightfoot H.,Cokelaer T.,Greninger P.,van Dyk E.,Chang H.,de Silva H.,Heyn H.,Deng X.,Egan R.K.,Liu Q.,Mironenko T.,Mitropoulos X.,Richardson L.,Wang J.,Zhang T.,Moran S.,Sayols S.,Soleimani M.,Tamborero D.,Lopez-Bigas N.,Ross-Macdonald P.,Esteller M.,Gray N.S.,Haber D.A.,Stratton M.R.,Benes C.H.,Wessels L.F.A.,Saez-Rodriguez J.,McDermott U.,Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)
PubMed=30894373;DOI=10.1158/0008-5472.CAN-18-2747
Dutil J.,Chen Z.,Monteiro A.N.,Teer J.K.,Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res.79:1263-1273(2019)
產(chǎn)品規(guī)格：T25培養(yǎng)瓶x1；1.5ml凍存管x2
細胞數(shù)量：1x10^6；1x10^6
保存溫度：37℃；-198℃
運輸方式：常溫保溫運輸；干冰運輸
安全等級：1
用途限制：僅供科研2類
培養(yǎng)體系：DMEM高糖培養(yǎng)基+10%FBS+1%三抗
培養(yǎng)溫度：37℃
二氧化碳濃度：5%
簡介：人黑色素瘤細胞WM35取自24歲女性供體
注釋
Part of:Cancer Cell Line Encyclopedia(CCLE)project.
Part of:COSMIC cell lines project.
Part of:Wistar Institute melanoma cell line collection.
Microsatellite instability:Stable(MSS)(Sanger).
Omics:Deep exome analysis.
Omics:DNA methylation analysis.
Omics:Transcriptome analysis.
Caution:The reported STR profile from Wistar of this cell line was changed at one point between February 2016 when we retrieved them and entered them in the Cellosaurus and May 2018.The major changes were:D18S51:20->14,15 and FGA:19->19,24.
基因突變
Heterozygous for BRAF p.Val600Glu(c.1799T>A)(PubMed=18632627;Wistar).
HLA信息
/
STR信息
Amelogenin X
CSF1PO 10
D2S1338 18,25
D3S1358 16,18
D5S818 11,12
D7S820 10,13
D8S1179 11,13
D13S317 11
D16S539 12,13
D18S51 14,15
D19S433 15,16
D21S11 29,32.2
FGA 19,24
TH01 9.3
TPOX 8
vWA 17
參考文獻
PubMed=23039341;DOI=10.1186/1476-4598-11-75
Byron S.A.,Loch D.C.,Wellens C.L.,Wortmann A.,Wu J.,Wang J.,Nomoto K.,Pollock P.M.
Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status.
Mol.Cancer 11:75-75(2012)
PubMed=27087056;DOI=10.1038ep24569
Haridas P.,McGovern J.A.,Kashyap A.S.,McElwain D.L.S.,Simpson M.J.
Standard melanoma-associated markers do not identify the MM127 metastatic melanoma cell line.
Sci.Rep.6:24569-24569(2016)
PubMed=27397505;DOI=10.1016/j.cell.2016.06.017
Iorio F.,Knijnenburg T.A.,Vis D.J.,Bignell G.R.,Menden M.P.,Schubert M.,Aben N.,Goncalves E.,Barthorpe S.,Lightfoot H.,Cokelaer T.,Greninger P.,van Dyk E.,Chang H.,de Silva H.,Heyn H.,Deng X.,Egan R.K.,Liu Q.,Mironenko T.,Mitropoulos X.,Richardson L.,Wang J.,Zhang T.,Moran S.,Sayols S.,Soleimani M.,Tamborero D.,Lopez-Bigas N.,Ross-Macdonald P.,Esteller M.,Gray N.S.,Haber D.A.,Stratton M.R.,Benes C.H.,Wessels L.F.A.,Saez-Rodriguez J.,McDermott U.,Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)
PubMed=30894373;DOI=10.1158/0008-5472.CAN-18-2747
Dutil J.,Chen Z.,Monteiro A.N.,Teer J.K.,Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res.79:1263-1273(2019)
